[28P-am] 医薬品情報②／薬剤管理指導・TDM／地域医療③／薬物治療（臨床・がん）②／リスクマネジメント・その他

[28P-am036S] ABCG2 genetic polymorphisms affect adverse events of afatinib, EGFR tyrosine kinase inhibitor, in patients with non-small cell lung cancer

○Nao Komizo¹, Hideki Hayashi^1,2, Hirotoshi Iihara^1,2, Chiemi Hirose², Yoshihisa Fukuda¹, Shogo Kamimori¹, Tomohiro Osawa³, Toshiyuki Sawa⁴, Yasushi Ohno⁵, Akio Suzuki^1,2, Tadashi Sugiyama¹ (1. Gifu Pharm. Univ., 2. Dept. Pharm., Gifu Univ. Hosp., 3. Dept. Pharm., Gifu Municipal. Hosp., 4. Div. Respiratory Med and Oncol., Gifu Municipal. Hosp., 5. 2nd Dept. Intern. Med., Gifu Univ. Sch. Med.)